Skip to main content

Table 1 Characteristics of patients at enrolment into the IPF-PRO Registry (n = 662)

From: Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry

Age, years 70 (65, 75)
Male 496 (74.9)
White 623 (94.1)
Body mass index, kg/m2 29.0 (26.0, 32.4)
Private insurance 420 (66.4)
Current or former smoker 446 (68.4)
Oxygen use with activity 217 (34.1)
Oxygen use at rest 125 (19.6)
Serologic testing reported at enrolment
 At least one abnormal serologic test reported
184 (27.8)
161
Receiving immunosuppressive or cytotoxic medications 5 (0.8)
Receiving nintedanib or pirfenidone 352 (54.0)
Surgical lung biopsy performed prior to enrolment 176 (30)
Bronchoscopy performed within 12 months of enrolment 60 (10.3)
Prior diagnosis of IPF (confirmed at the enrolling centre) 301 (45)
Diagnostic criteriaa
 Definite IPF 437 (68.8)
 Probable IPF 141 (22.2)
 Possible IPF 57 (9.0)
History of coronary artery disease or congestive heart failure 203 (31.2)
History of pulmonary hypertension 51 (7.9)
Emphysemab 71 (11.2)
Prior hospitalisation (any) 171 (29.3)
 Respiratory related 106 (18.2)
 Non-respiratory related 86 (14.8)
Symptom onset to confirmed diagnosis of IPF at enrolling center, months 14 (7, 29)
Distance to enrolling centre, miles 40 (16, 109)
FVC, % predicted 69.6 (60.1, 79.9)
DLco, % predicted 41.7 (32.2, 50.1)
Prior respiratory hospitalisation 106 (18.2)
 1 84 (12.7)
 2 18 (2.7)
 3 3 (0.5)
 4 1 (0.2)
Composite physiologic index 53.2 (45.7, 60.0)
GAP stage
 I 146 (26.4)
 II 306 (55.2)
 III 102 (18.4)
  1. Data are median (25th, 75th percentile) or n (%). Not all patients provided data on all variables. aAccording to 2011 ATS/ERS/JRS/ALAT diagnostic guidelines [1]. bClinically significant emphysema on HRCT scan (based on the opinion of the investigator)